COMMUNIQUÉS West-GlobeNewswire

Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio
28/05/2026
BASEL, Switzerland, May 28, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system for the treatment of autoimmune and inflammatory diseases, today [...]
Groundbreaking therapy for advanced heart failure: Outcomes of the BIOVAT-HF clinical trial published in NEJM
28/05/2026
Repairon Announces Publication of Clinical Trial Results for Engineered Human Heart Muscle Tissue in the New England Journal of Medicine GÖTTINGEN, Germany and PROVIDENCE, R.I., May 28, 2026 (GLOBE NEWSWIRE) -- Repairon [...]
ViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit Economics
28/05/2026
Commercial-scale production of Kaleido consumables begins at contract manufacturer Phillips Medisize Manufacturing capacity more than triples, with initial capacity to support over 17,000 users Volume manufacturing [...]
argenx to Host Myositis R&D Webinar on June 23, 2026
28/05/2026
May 28, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will [...]
De nouvelles données "late-breaking" renforcent l’impact d’IQIRVO® sur l’ALP, la fatigue et le prurit dans la CBP.
28/05/2026
Les données concernant IQIRVO ® viennent enrichir les connaissances scientifiques sur la fatigue, en montrant des améliorations cliniquement significatives chez des patients présentant une fatigue modérée à sévère à l’ [...]
Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma
28/05/2026
Orphan Drug Designation confers regulatory, financial and strategic advantages EO2463 has shown potentially disease modifying activity in clinical testing in watch-and-wait iNHL patients EO2463 has shown complementary [...]
Communiqué de presse : Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3
28/05/2026
Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3 Paris, le 28 mai 2026. L’Agence américaine des produits alimentaires et médicamenteux ( [...]
New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC
28/05/2026
IQIRVO ® data expands scientific evidence in fatigue, showing clinically meaningful improvements in patients with moderate-to-severe fatigue at baseline In the first real-world analysis in patients with PBC and an ALP 1 [...]
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
28/05/2026
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, May 28, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients [...]
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
28/05/2026
Transactions Provide Financial Flexibility to Advance Pipeline of Next Generation Cancer Therapies Comprised of Novel Bispecific T-cell Engagers (TCEs) and Antibody-Drug Conjugates (ADCs) Support Closing of Business [...]
Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma
28/05/2026
UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapy TGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that selectively activates [...]
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
28/05/2026
Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026 . The US Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) [...]
BioNature Berberine Claims Evaluated: Premium Berberine AMPK Activator Supplement for Blood Sugar & Metabolism Support
28/05/2026
Two-Product Berberine and Chromium Picolinate Protocol for AMPK Support, Insulin Sensitivity, and Healthy Blood Sugar Levels Explained Miami, FL, May 27, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated [...]
Memora Supplement Under Investigation: Effective Brain Booster Formula Against EMF Radiation - Latest Memory Health Report
28/05/2026
Bacopa Monnieri, Lion's Mane, and Ginkgo Biloba Cognitive Formula - Ingredients, Side Effects, Complaints, and Refund Policy Explained New York, NY, May 27, 2026 (GLOBE NEWSWIRE) -- These statements have not been [...]
CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
27/05/2026
MINNEAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Sana Biotechnology to Present at June 2026 Investor Conferences
27/05/2026
SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations [...]
Ligand to Participate in June Investor Conferences
27/05/2026
JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Stifel [...]
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
27/05/2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy
27/05/2026
Appointments enhance commercialization readiness as Zentalis advances registrational program for azenosertib in Cyclin-E1 positive platinum-resistant ovarian cancer SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Zentalis® [...]

Pages